Ficlatuzumab
Wiki90
Wiki90: 90s Style Encyclopedia on the Web
|
|
|
|
Ficlatuzumab
In this article, we will explore the topic of Ficlatuzumab in depth, examining its origins, its impact on contemporary society and its relevance in different areas of daily life. In order to better understand this phenomenon, we will delve into its history, analyze different perspectives and give a voice to experts in the field. Throughout these pages, I invite the reader to reflect on Ficlatuzumab from various perspectives and to question their own preconceived ideas about it. I hope that this article proves to be a source of knowledge and inspiration, and that it contributes to enriching the dialogue around Ficlatuzumab.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6446H9954N1718O2026S46 |
| Molar mass | 145409.30 g·mol−1 |
  (what is this?) (verify) | |
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.
It is a humanized monoclonal antibody that binds to hepatocyte growth factor, thus inhibiting the c-MET receptor signaling cascade.
Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
- ^ Panahi Y, Mohammadzadeh AH, Behnam B, Orafai HM, Jamialahmadi T, Sahebkar A (2021). "A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer". Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology. Vol. 1286. pp. 49–64 (57). doi:10.1007/978-3-030-55035-6_3. ISBN 978-3-030-55034-9. PMID 33725344. S2CID 232261340.
- ^ "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |